Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Blood (2021) 138 (24): 2469–2484.

https://doi.org/10.1182/blood.2021011898

Published: 2021

Includes: Supplemental data

Journal Articles

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Sara K. Silbert, Elizabeth M. Holland, Seth M. Steinberg, Lauren Little, Toni Foley, Haneen Shalabi, Bonnie Yates, Nirali N. Shah

Blood (2021) 138 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2021-146979

Published: 2021

Journal Articles

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Bonnie Yates, RN, Haneen Shalabi, DO, Dalia Salem, MD, Cynthia Delbrook, RN, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Nirali N. Shah, MD

Blood (2018) 132 (Supplement 1): 282.

https://doi.org/10.1182/blood-2018-99-119621

Published: 2018

Journal Articles

Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration

Sandeep K Srivastava, PhD, Sandhya R. Panch, MD MPH, Jianjian Jin, PhD, Haneen Shalabi, DO, Nirali N. Shah, MD, Steven L Highfill, PhD, David F. Stroncek

Blood (2018) 132 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2018-99-116846

Published: 2018

Journal Articles

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Nirali N Shah, MD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Alina Dulau-Florea, MD, Anne Cullinane, BS, Cynthia Delbrook, RN, Michael Ombrello, MD, Amanda Ombrello, MD, Jay Nelson Lozier, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1277.

https://doi.org/10.1182/blood.V130.Suppl_1.1277.1277

Published: 2017

Journal Articles

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Nirali N Shah, MD, Steven L Highfill, PhD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Vicki Fellowes, Cynthia Delbrook, RN, Jiaqiang Ren, MD PhD, Jianjian Jin, David Stroncek, MD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 809.

https://doi.org/10.1182/blood.V130.Suppl_1.809.809

Published: 2017

Journal Articles

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN, Constance Yuan, Maryalice Stetler-Stevenson, Sneha Ramakrishna, MD

Blood (2017) 130 (Supplement 1): 3889.

https://doi.org/10.1182/blood.V130.Suppl_1.3889.3889

Published: 2017

Journal Articles

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN

Blood (2017) 130 (Supplement 1): 5048.

https://doi.org/10.1182/blood.V130.Suppl_1.5048.5048

Published: 2017

Journal Articles

Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy

Haneen Shalabi, DO, Haiying Qin, MS, Kelsey Wanhainen, BS, Jillian Smith, BS, Rimas Orentas, PhD, Nirali N Shah, MD, Shannon L Maude, MD PhD, Sarah K Tasian, MD, David T Teachey, MD, Javed Khan, MD, Terry J Fry, MD

Blood (2016) 128 (22): 4019.

https://doi.org/10.1182/blood.V128.22.4019.4019

Published: 2016

Journal Articles

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Haneen Shalabi, DO, Pamela L Wolters, PhD, Staci Martin, PhD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Daniel W. Lee, III, MD, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 1625.

https://doi.org/10.1182/blood.V128.22.1625.1625

Published: 2016

Journal Articles

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Haneen Shalabi, DO, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD, Terry J Fry, MD

Blood (2016) 128 (22): 650.

https://doi.org/10.1182/blood.V128.22.650.650

Published: 2016

Journal Articles

Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS

Kazusa Ishii, MD MPH, Haneen Shalabi, DO, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 3358.

https://doi.org/10.1182/blood.V128.22.3358.3358

Published: 2016

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only